Bengaluru: Sayre Therapeutics, a commercial healthcare company with a portfolio of oncology and immunology focussed commercial products, has announced that it has entered into an exclusive license agreement (the License Agreement) with GP Pharm S.A. (GP Pharm) to distribute, market and sell LUTRATE® Depot in 1 and 3 month formulations in India, Sri Lanka, Bangladesh and Nepal. GP Pharm will supply LUTRATE® to Sayre on an exclusive basis from its manufacturing facility in Barcelona, Spain.
Ms Vandana Subramanian, Senior Vice-President, BD & Corporate Strategy mentioned “Our collaboration with GP Pharm helps us bring an EMA approved best-in-class differentiated Leuprolide Acetate depot formulation to South Asia. This medicine provides a further fillip to our efforts to build a portfolio for oncology diseases with advanced options for patients suffering from prostate cancer. LUTRATE® will greatly benefit the South Asian patient community and improve their quality of life. “
“We are extremely pleased that we have been able to expand the availability of LUTRATE® to the South-Asian region with our committed and capable partner, Sayre Therapeutics”, said Dr Antonio Parente, GP Pharm’s Executive President. “This collaboration represents one step further in our worldwide expansion and it will allow us to position Lutrate® in new territories and continue with the corporate vision of GP Pharm: bringing science to the society by developing innovative products.”
